M-See list of specific histologies below. All primary sites (C00.0-C80.9) are included unless otherwise specified. Schema includes only preferred terms from ICD-O-3. Plasmacytomas (9731 and 9734) and Multiple Myeloma (9732), except for cases with primary site C441, C690 and C695-C696, have been moved to the MyelomaPlasmaCellDisorder schema in V0203 9733 Plasma cell leukemia [except C441, C690, C695-C696] 9740 Mast cell sarcoma 9741 Malignant mastocytosis 9742 Mast cell leukemia 9750 Malignant histiocytosis 9752 Langerhans cell histiocytosis, unifocal* (see new reportable code 9751/3) 9753 Langerhans cell histiocytosis, multifocal* (see new reportable code 9751/3) 9754 Langerhans cell histiocytosis disseminated 9755 Histiocytic sarcoma 9756 Langerhans cell sarcoma 9757 Interdigitating dendritic cell sarcoma 9758 Follicular dendritic cell sarcoma 9760 Immunoproliferative disease, NOS 9761 Waldenstrom macroglobulinemia 9762 Heavy chain disease, NOS 9764 Immunoproliferative small intestinal disease 9765 Monoclonal gammopathy of undetermined significance* 9766 Angiocentric immunoproliferative lesion* 9767 Angioimmunoblastic lymphadenopathy* 9768 T-gamma lymphoproliferative disease* 9769 Immunoglobulin deposition disease* 9800 Leukemia, NOS 9801 Acute leukemia, NOS 9805 Acute biphenotypic leukemia 9820 Lymphoid leukemia, NOS [except C441, C690, C695-C696] 9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma [C420, C421, or C424 ONLY] 9826 Burkitt cell leukemia leukemia [except C441, C690, C695-C696] 9827 Adult T-cell leukemia/lymphoma (HTLV-1 positive)[C420, C421, or C424 ONLY] 9832 Prolymphocytic leukemia, NOS [except C441, C690, C695-C696] 9833 Prolymphocytic leukemia, B-cell type [except C441, C690, C695-C696] 9834 Prolymphocytic leukemia, T-cell type [except C441, C690, C695-C696] 9835 Precursor cell lymphoblastic leukemia, NOS [except C441, C690, C695-C696] 9836 Precursor B-cell lymphoblastic leukemia [except C441, C690, C695-C696] 9837 Precursor T-cell lymphoblastic leukemia [see 9837 below, new definition] 9840 Acute myeloid leukemia, M6 type 9860 Myeloid leukemia, NOS 9861 Acute myeloid leukemia, NOS 9863 Chronic myeloid leukemia 9866 Acute promyelocytic leukemia 9867 Acute myelomonocytic leukemia 9870 Acute basophilic leukemia 9871 Acute myeloid leukemia with abnormal marrow, eosinophils 9872 Acute myeloid leukemia, minimal differentiation 9873 Acute myeloid leukemia without maturation 9874 Acute myeloid leukemia with maturation 9875 Chronic myelogenous leukemia, BCR/ABL positive 9876 Atypical chronic myeloid leukemia BCR/ABL negative 9891 Acute monocytic leukemia 9895 Acute myeloid leukemia with multilineage dysplasia 9896 Acute myeloid leukemia, t(8;21)(q22;q22) 9897 Acute myeloid leukemia, 11q23 abnormalities 9910 Acute megakaryoblastic leukemia 9920 Therapy-related acute myeloid leukemia, NOS 9930 Myeloid sarcoma 9931 Acute panmyelosis with myelofibrosis 9940 Hairy cell leukemia 9945 Chronic myelomonocytic leukemia, NOS 9946 Juvenile myelomonocytic leukemia 9948 Aggressive NK-cell leukemia 9950 Polycythemia (rubra) vera 9960 Chronic myeloproliferative disease, NOS 9961 Myelosclerosis with myeloid metaplasia 9962 Essential thrombocythemia 9963 Chronic neutrophilic leukemia 9964 Hypereosinophilic syndrome 9970 Lymphoproliferative disorder, NOS* 9975 Myeloproliferative disease, NOS* 9980 Refractory anemia, NOS 9982 Refractory anemia with sideroblasts 9983 Refractory anemia with excess blasts 9984 Refractory anemia with excess blasts in transformation 9985 Refractory cytopenia with multilineage dysplasia 9986 Myelodysplastic syndrome with 5q deletion (5q-) syndrome 9987 Therapy-related myelodysplastic syndrome, NOS 9989 Myelodysplastic syndrome, NOS The following ICD-O codes were added to the reportable list for Hematopoietic diseases. These are from the "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 3rd edition" publication, which was released in 2008. These new codes have been incorporated into the new Hematopoietic and Lymphoid Neoplasm MP/H rules. Use these only for cases diagnosed on January 1, 2010 and forward. 9751 Langerhans cell histiocytosis, NOS 9806 Mixed phenotype acute leukemia with t(9;22(q34;q11.2); BCR-ABL1 9807 Mixed phenotype acute leukemia with t(v;11q23); MLL, rearranged 9808 Mixed phenotype acute leukemia, B/myeloid, NOS 9809 Mixed phenotype acute leukemia, T/myeloid, NOS 9811 B lymphoblastic leukemia/lymphoma, NOS [C420, C421, or C424 ONLY] 9812 B lymphoblastic leukemia/lymphoma with t(9;22))q34;q11.2); BCR-ABL1 [C420, C421, or C424 ONLY] 9813 B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged [C420, C421, or C424 ONLY] 9814 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) [C420, C421, or C424 ONLY] 9815 B lymphoblastic/lymphoma with hyperdiploidy[C420, C421, or C424 ONLY] 9816 B lymphoblastic/lymphoma with hypodiploidy (hypodiploid ALL) [C420, C421, or C424 ONLY] 9817 B lymphoblastic/lymphoma with t(5;14)(q31;q32); IL3-IGH [C420, C421, or C424 ONLY] 9818 B lymphoblastic/lymphoma with t(1;19)(q23;p13.3); E2A PBX1 (TCF3 PBX1) [C420, C421, or C424 ONLY] 9831 T-cell large granular lymphocytic leukemia [except C441, C690, C695-C696] 9837 T lymphoblastic leukemia/lymphoma [C420, C421, or C424 ONLY] 9865 Acute myeloid leukemia with t(6;9)([23;q34) DEK-NUP214 9869 Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26;2); RPN1EVI1 9898 Myeloid leukemia associated with Down Syndrome 9911 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 9965 Myeloid and lymphoid neoplasms with PDGFRA rearrangement 9966 Myeloid neoplasm with PDGFRB rearrangement 9967 Myeloid and lymphoid neoplasm with FGFR1 abnormalities 9971 Polymorphic PTLD 9975 Myeloproliferative neoplasm, unclassifiable 9991 Refractory neutropenia 9992 Refractory thrombocytopenia *Usually considered of uncertain/borderline behavior Note: AJCC does not define TNM staging for this site. ¬appsizenontnm; CS Extension Note: Plasmacytomas (9731 and 9734) and Multiple Myeloma (9732) have been moved to the MyelomaPlasmaCellDisorder schema effective with CS version 2: 0203 Code Description TNM 7 Map TNM 6 Map SS77 Map SS2000 Map 100 NA NA L L 800 NA NA D D 999 NA NA D D ¬appcsextevalnontnm; ¬applymphnodes; ¬appcsregnodesevalnontnm; ¬appreglnpos; ¬appreglnexam; ¬appcsmetsatdx; ¬appcsmetsevalnontnm; CS Site-Specific Factor 1 JAK2 (also known as Janus Kinase 2 and JAK2 Exon 12) Note 1: Janus Kinase 2 (JAK2, JAK 2)is a gene mutation that increases susceptibility to several myeloproliferative neoplasms (MPNs). Testing for the JAK2 mutation is done on whole blood. Nearly all people with polycythemia vera and about half of those with essential thrombocythemia and primary myelofibrosis have the mutation. Note 2: JAK2 is used primarily for the following histologies: Polycythemia Vera, Essential Thrombocytopenia, and Primary Myelofibrosis. Its usage continues to increase and may be used for other histologies in the future. Record JAK2 for any hematopoietic/reticuloendothelial disease even if it is not one of these three specific histologies. Note 3: If JAK2 test result is positive, NOS, use code 850. Code Description 000 JAK-2 result stated as negative 010 JAK2 positive for mutation V617F in exon 14 020 JAK2 positive for mutation of exon 12 800 JAK2 positive for other specified mutation 810 JAK2 positive for more than one mutation 850 JAK2 positive NOS; specific mutation(s) not stated 888 988 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 ¬appssfactor2; ¬appssfactor3; ¬appssfactor4; ¬appssfactor5; ¬appssfactor6; ¬appnewssf7; ¬appnewssf8; ¬appnewssf9; ¬appnewssf10; ¬appnewssf11; ¬appnewssf12; ¬appnewssf13; ¬appnewssf14; ¬appnewssf15; ¬appnewssf16; ¬appnewssf17; ¬appnewssf18; ¬appnewssf19; ¬appnewssf20; ¬appnewssf21; ¬appnewssf22; ¬appnewssf23; ¬appnewssf24; ¬appnewssf25; ¬apphistologiestnm7; ¬appsajcchistdrivensites; ¬appcsstagetnm7; ¬appcsstage; &commonsummarystage;